MITO
Price:
$0.32
Market Cap:
$0
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to tr...[Read more]
Industry
Biotechnology
IPO Date
2019-02-15
Stock Exchange
NASDAQ
Ticker
MITO
According to Stealth BioTherapeutics Corp’s latest financial reports and current stock price. The company's current PE Ratio is -0.35. This represents a change of -84.04% compared to the average of -2.17 of the last 4 quarters.
The mean historical PE Ratio of Stealth BioTherapeutics Corp over the last ten years is -2.28. The current -0.35 PE Ratio has changed 1.42% with respect to the historical average. Over the past ten years (40 quarters), MITO's PE Ratio was at its highest in in the December 2019 quarter at 7.95. The PE Ratio was at its lowest in in the June 2019 quarter at -7.13.
Average
-2.28
Median
-1.85
Minimum
-4.06
Maximum
-0.72
Discovering the peaks and valleys of Stealth BioTherapeutics Corp PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 78.20%
Maximum Annual PE Ratio = -0.72
Minimum Annual Increase = -64.98%
Minimum Annual PE Ratio = -4.06
Year | PE Ratio | Change |
---|---|---|
2021 | -0.72 | -40.67% |
2020 | -1.21 | -15.24% |
2019 | -1.42 | -64.98% |
2018 | -4.06 | 78.20% |
2017 | -2.28 | -42.62% |
The current PE Ratio of Stealth BioTherapeutics Corp (MITO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.11
5-year avg
-1.94
10-year avg
-2.28
Stealth BioTherapeutics Corp’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stealth BioTherapeutics Corp using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Stealth BioTherapeutics Corp or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Stealth BioTherapeutics Corp's PE Ratio?
How is the PE Ratio calculated for Stealth BioTherapeutics Corp (MITO)?
What is the highest PE Ratio for Stealth BioTherapeutics Corp (MITO)?
What is the 3-year average PE Ratio for Stealth BioTherapeutics Corp (MITO)?
What is the 5-year average PE Ratio for Stealth BioTherapeutics Corp (MITO)?
How does the current PE Ratio for Stealth BioTherapeutics Corp (MITO) compare to its historical average?